JP2014532727A5 - - Google Patents

Download PDF

Info

Publication number
JP2014532727A5
JP2014532727A5 JP2014540166A JP2014540166A JP2014532727A5 JP 2014532727 A5 JP2014532727 A5 JP 2014532727A5 JP 2014540166 A JP2014540166 A JP 2014540166A JP 2014540166 A JP2014540166 A JP 2014540166A JP 2014532727 A5 JP2014532727 A5 JP 2014532727A5
Authority
JP
Japan
Prior art keywords
patent document
application publication
patent application
international
prior
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014540166A
Other languages
English (en)
Japanese (ja)
Other versions
JP6205095B2 (ja
JP2014532727A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/063447 external-priority patent/WO2013067449A1/en
Publication of JP2014532727A publication Critical patent/JP2014532727A/ja
Publication of JP2014532727A5 publication Critical patent/JP2014532727A5/ja
Application granted granted Critical
Publication of JP6205095B2 publication Critical patent/JP6205095B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014540166A 2011-11-03 2012-11-02 疎水性カンプトテシン誘導体の医薬組成物 Expired - Fee Related JP6205095B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161555084P 2011-11-03 2011-11-03
US61/555,084 2011-11-03
PCT/US2012/063447 WO2013067449A1 (en) 2011-11-03 2012-11-02 Pharmaceutical compositions of hydrophobic camptothecin derivatives

Publications (3)

Publication Number Publication Date
JP2014532727A JP2014532727A (ja) 2014-12-08
JP2014532727A5 true JP2014532727A5 (enExample) 2015-11-05
JP6205095B2 JP6205095B2 (ja) 2017-09-27

Family

ID=48192863

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014540166A Expired - Fee Related JP6205095B2 (ja) 2011-11-03 2012-11-02 疎水性カンプトテシン誘導体の医薬組成物

Country Status (12)

Country Link
US (1) US10391056B2 (enExample)
EP (1) EP2773346B1 (enExample)
JP (1) JP6205095B2 (enExample)
KR (1) KR101688898B1 (enExample)
CN (1) CN103957912B (enExample)
AU (1) AU2012332176B2 (enExample)
CA (1) CA2850955C (enExample)
IN (1) IN2014DN00277A (enExample)
SG (1) SG10201609199YA (enExample)
TW (3) TWI480042B (enExample)
WO (1) WO2013067449A1 (enExample)
ZA (1) ZA201403195B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1217092A1 (zh) 2013-02-15 2016-12-23 Kala Pharmaceuticals, Inc. 治疗性化合物及其用途
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
BR112015020139A2 (pt) 2013-02-20 2017-07-18 Kala Pharmaceuticals Inc compostos terapêuticos e usos dos mesmos
TWI526446B (zh) 2013-09-27 2016-03-21 中國醫藥大學附設醫院 喜樹鹼的新穎20(s)-磺基脒衍生物及其抗腫瘤劑的用途
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036336A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
JP6826737B2 (ja) * 2018-01-19 2021-02-10 Delta−Fly Pharma株式会社 がん患者の治療に有用な尿のアルカリ剤
CN111632144B (zh) * 2020-07-06 2022-07-29 聊城大学 一种高载药量的光-化疗双功能纳米粒及其制备方法
CN116917009A (zh) 2021-02-19 2023-10-20 美国迈胜医疗系统有限公司 用于粒子治疗系统的机架
AR125473A1 (es) 2021-04-29 2023-07-19 Abbvie Inc Conjugados de anticuerpo anti-c-met y fármaco
AU2023359114A1 (en) 2022-10-09 2025-04-24 LaNova Medicines Limited Compounds, compositions and methods

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5731316A (en) 1996-01-30 1998-03-24 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
AU2001258106A1 (en) 2000-05-11 2001-11-20 Celator Technologies Inc. Lipid carrier compositions for improved drug retention
US7485320B2 (en) * 2000-09-25 2009-02-03 Industrial Technology Research Institute Liposome for incorporating large amounts of hydrophobic substances
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
ES2594621T3 (es) 2004-06-01 2016-12-21 Kabushiki Kaisha Yakult Honsha Preparación de irinotecán
EP1759699B1 (en) * 2004-06-18 2016-01-20 Kabushiki Kaisha Yakult Honsha Liposome preparation containing slightly water-soluble camptothecin
JP4990786B2 (ja) * 2004-11-05 2012-08-01 イネックス ファーマシューティカルズ コーポレイション 薬物リポソーム製剤を安定化するための組成物および方法
WO2007017513A2 (en) * 2005-08-10 2007-02-15 Novartis Ag Formulations for 7-(t-butoxy)iminomethyl camptothecin
US7875602B2 (en) * 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
AU2008210511A1 (en) 2007-02-01 2008-08-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative
CN101283983A (zh) 2007-10-26 2008-10-15 南京长澳医药科技有限公司 一种稳定的喜树碱类药物脂质体组合物
CN101485629B (zh) 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
US8168648B2 (en) 2009-03-06 2012-05-01 Taiwan Liposome Co., Ltd. Camptothecin derivatives and uses thereof
CN101869712B (zh) 2009-04-21 2016-01-20 财团法人工业技术研究院 使用包囊抗肿瘤药物的聚合胶束用于治疗肿瘤的药物组合物
CN102018670B (zh) 2010-11-15 2015-08-12 宜昌人福药业有限责任公司 一种抗癌制剂
US20140135357A1 (en) 2012-11-12 2014-05-15 Taiwan Liposome Company, Ltd. Dose regime for camptothecin derivatives

Similar Documents

Publication Publication Date Title
JP2014532727A5 (enExample)
JP2014519662A5 (enExample)
JP2014528601A5 (enExample)
JP2014513356A5 (enExample)
IL268756B (en) Piperazine-2,5-dione derivatives, pharmaceutical preparations containing them and their use for the preparation of medicines
JP2014513484A5 (enExample)
JP2014138100A5 (enExample)
MX2013014788A (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.
JP2013517798A5 (enExample)
HRP20180709T1 (hr) Farmaceutski dozni oblik kapsule koji obuhvaća suspenzijsku formulaciju derivata indolinona
MA32383B1 (fr) DÉRIVÉS D'INDAZOLES à SUBSTITUTIONS PHÉNYLE ET BENZODIOXYNYLE
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
ATE541841T1 (de) Inhibitoren der replikation des human immunodeficiency virus
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
JP2014520090A5 (enExample)
DK3045164T3 (da) Vandige farmaceutiske sammensætninger, der indeholder borat-polyol-komplekser
ECSP11011555A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
JP2015518494A5 (enExample)
HK1209638A1 (en) Pharmaceutical compositions
JP2014533241A5 (enExample)
JP2014508098A5 (enExample)
UY32618A (es) Combinación antitumoral que comprende ave8062 y sorafenib
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
MY173851A (en) Isomaltulose for use in enhancing mental performance
EA201590752A1 (ru) Препараты производных пиримидиндиона